Renal Physiology VII Flashcards
(100 cards)
Since the ability of the liver to respond to insulin is impaired, hepatic gluconeogenesis is upregulated, setting in motion a viscious cycle of
Hyperglycemia and hyperinsulinemia
Obesity is defined as a body mass index (BMI) of
Greater than 30kg.m^2
The deposition of fat in the regions of the hip and buttocks is not strongly correlated with
Metabolic disease
Whereas accumulation of visceral fat is linked with a syndrome that is described as
Type 2 DM
The distribution of fat around the abdominal wall and visceral mesenteric location
Android obesity
On the other hand, the presence of subcutaneous abdominal fat has less of an association with
Insulin resistance
Correlated with the development of hypertension and dyslipidemia, among other risk factors for cardiovascular disease
Android obesity
The android obesity phenotype results in an abnormally increased
Waist-to-hip tatio (greater than 0.9 in males and 0.85 in females)
Has a gene expression pattern that makes it distinct from other fat stores
Visceral fat
Mutations and/or abnormal expression/activity of adipokines (e.g., adiponectin and leptin), cytokines (e.g., tumor necrosis factor-a, TNFa), and FFA which are produced by visceral fat have the ability to alter both
Glucose metabolism and Insulin sensitivity
Each increae sensitivity to insulin
Leptin and adiponectin
Has been shown to impede insulin dependent glucose metabolism
TNFa
Impede both insulin secretion and insulin-directed glucose uptake in peripheral tissues
FFAs
FFAs stimulate dipocytes to secrete
TNFa
TNFa in turn exerts positive feedback on
FFA secretion
In response to insulin resistance, visceral fat undergoes
Lipolysis
The lypolysis that visceral fat undergoes results in increased levels of
Tryglycerides and small and dense LDL (the really bad kind of LDL) and decreased HDL
Visceral fat thus increases
CV risk
It is therefore important to realize that visceral abdominal fat is very active in terms of its production of a cohort of factors which
Impede insulin secretion and impair insulin-dependent glucose uptake
The ideal goals for preventing the progression of IGT to Type 2 DM
Weight loss and exercise
A biguanide that impairs hepatic gluconeogenisis and intestinal glucose absorption, and enhances peripheral glucose uptake
Metformin
An insulin sensitizer
Thiazolideniones (pioglitazone)
Insulin secretagogues that promote endogenous insulin production
Sulfonylureas
Injectables or insulin pump that can replace pancreatic and islet cells
Insulin replacement